Innate Pharma Stock Forecast, Price & News

-0.09 (-2.07 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $4.26
50-Day Range
MA: $4.42
52-Week Range
Now: $4.26
Volume1,903 shs
Average Volume39,986 shs
Market Capitalization$336.50 million
P/E RatioN/A
Dividend YieldN/A
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
Innate Pharma logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:IPHA
Year FoundedN/A



Sales & Book Value

Annual Sales$96.12 million
Book Value$3.18 per share



Market Cap$336.50 million
Next Earnings DateN/A
OptionableNot Optionable


See More Headlines


Overall MarketRank

1.07 out of 5 stars

Medical Sector

1000th out of 2,010 stocks

Biological Products, Except Diagnostic Industry

132nd out of 177 stocks

Analyst Opinion: 3.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.09 (-2.07 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPHA News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Innate Pharma (NASDAQ:IPHA) Frequently Asked Questions

Is Innate Pharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Innate Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPHA, but not buy additional shares or sell existing shares.
View analyst ratings for Innate Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Innate Pharma?

Wall Street analysts have given Innate Pharma a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Innate Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Innate Pharma?

Innate Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 7,500 shares, an increase of 53.1% from the February 28th total of 4,900 shares. Based on an average daily trading volume, of 39,500 shares, the short-interest ratio is currently 0.2 days.
View Innate Pharma's Short Interest

How has Innate Pharma's stock been impacted by Coronavirus (COVID-19)?

Innate Pharma's stock was trading at $6.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPHA shares have decreased by 32.4% and is now trading at $4.26.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IPHA?

4 brokers have issued twelve-month price objectives for Innate Pharma's stock. Their forecasts range from $4.75 to $13.00. On average, they expect Innate Pharma's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 93.7% from the stock's current price.
View analysts' price targets for Innate Pharma
or view top-rated stocks among Wall Street analysts.

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the following people:
  • Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 63, Pay $1.14M)
  • Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA, Exec. VP, CFO & Member of Exec. Board (Age 43, Pay $353.42k)
  • Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 48, Pay $385.15k)
  • Dr. Herve Brailly, Co-Founder & Chairman of Supervisory Board (Age 60)
  • Dr. François Romagné, Founder (Age 57)
  • Mr. Eric Vivier D.V.M., M.B.A., Ph.D., Founder, Sr. VP & Chief Scientific Officer (Age 57)
  • Dr. Marc Bonneville, Founder (Age 61)
  • Mr. Jean Jacques Fournié Ph.D., Founder
  • Mr. Alessandro Moretta M.D., Ph.D., Founder
  • Danielle Spangler, Head of Investor Relations

What is Hervé Brailly's approval rating as Innate Pharma's CEO?

4 employees have rated Innate Pharma CEO Hervé Brailly on Hervé Brailly has an approval rating of 100% among Innate Pharma's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Innate Pharma's key competitors?

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), INmune Bio (INMB), Pluristem Therapeutics (PSTI) and (SNY).

When did Innate Pharma IPO?

(IPHA) raised $80 million in an IPO on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

What is Innate Pharma's stock symbol?

Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA."

How do I buy shares of Innate Pharma?

Shares of IPHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innate Pharma's stock price today?

One share of IPHA stock can currently be purchased for approximately $4.26.

How much money does Innate Pharma make?

Innate Pharma has a market capitalization of $336.50 million and generates $96.12 million in revenue each year. The company earns $-23,250,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Innate Pharma have?

Innate Pharma employs 247 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is

Where are Innate Pharma's headquarters?

Innate Pharma is headquartered at 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-4-30-30-30-30 or via email at [email protected]

This page was last updated on 4/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.